胡巍　蔡思敏　廖盛欢

【摘要】 目的：探討贝伐珠单抗联合化疗对非小细胞肺癌（NSCLC）患者免疫功能及生活质量的影响。方法：选择2017年11月-2020年1月就诊于本院的90例NSCLC患者。按随机数字表法将患者分为观察组和对照组，各45例。对照组行常规GP化疗方案治疗，观察组在对照组基础上加用贝伐珠单抗注射液治疗。比较两组临床疗效、免疫功能、生活质量、不良反应发生情况。结果：观察组治疗总有效率高于对照组，差异有统计学意义（P<0.05）。治疗后，观察组CD3、CD4、CD8、CD4/CD8均高于对照组，差异均有统计学意义（P<0.05）。治疗后，两组KPS评分均高于治疗前，且观察组高于对照组，差异均有统计学意义（P<0.05）。观察组血小板减少、肝功能损害、恶心/呕吐发生率均低于对照组，差异均有统计学意义（P<0.05）;两组白细胞减少、骨髓抑制发生率比较，差异均无统计学意义（P>0.05）。结论：贝伐珠单抗联合化疗治疗NSCLC患者能够有效控制肿瘤生长，提高免疫功能和生活质量，减少不良反应发生，安全性较高。

【关键词】 非小细胞肺癌 贝伐珠单抗 免疫功能 化疗 生活质量

Effect of Bevacizumab Combined with Chemotherapy on Immune Function and Quality of Life in Patients with Non-small Cell Lung Cancer/HU Wei， CAI Simin， LIAO Shenghuan. //Medical Innovation of China， 2021， 18（23）： 0-063

[Abstract] Objective： To investigate the effects of Bevacizumab combined with chemotherapy on immune function and quality of life in patients with non-small cell lung cancer （NSCLC）. Method： A total of 90 patients with NSCLC admitted to our hospital from November 2017 to January 2020 were selected. The patients were divided into observation group and control group by random number table method， 45 cases in each group. The control group received conventional GP chemotherapy， the observation group was treated with Bevacizumab Injection on the basis of the control group. Clinical efficacy， immune function， quality of life and the occurrence of adverse reactions were compared between the two groups. Result： The total effective rate of the observation group was higher than that of the control group， the difference was statistically significant （P<0.05）. After treatment， CD3+， CD4+， CD8+ and CD4+/CD8+ in the observation group were higher than those in the control group， the differences were statistically significant （P<0.05）. After treatment， KPS scores in both groups were higher than those before treatment， and the observation group was higher than that of the control group， the differences were statistically significant （P<0.05）. The incidence of thrombocytopenia， liver function damage and nausea/vomiting in the observation group were lower than those in the control group， the differences were statistically significant （P<0.05）. The incidence of leukopenia and bone marrow suppression were compared between the two groups， there were no significant differences （P>0.05）. Conclusion： Bevacizumab combined with chemotherapy in the treatment of NSCLC patients can effectively control tumor growth， improve immune function and quality of life， reduce adverse reactions and have high safety.

[Key words] Non-small cell lung cancer Bevacizumab Immune function Chemotherapy Quality of life

First-author’s address： Xinyu Second Hospital， Xinyu 338000， China

doi：10.3969/j.issn.1674-4985.2021.23.015

非小细胞肺癌（NSCLC）发病率约占肺癌的85%，因患者早期无典型性临床表现，不易受到重视，约57%患者就诊时病情已发展至ⅢB或Ⅳ期，错失手术治疗最佳时机，预后较差，死亡率较高[1-3]。针对此类患者临床多使用化疗方案治疗，其中GP方案较为常见，能够杀死或去除肿瘤组织，控制疾病发展，延长患者生存期，但仍有部分患者经GP化疗方案治疗后病情仍会进展，难以达到理想的治疗效果[4-5]。贝伐珠单抗属于重组抗人VEGF单克隆抗体，能高亲和力结合血管内皮生长因子（VEGF），减弱、阻止VEGF及其受体结合，发挥抗肿瘤作用，逐渐被应用于临床。……